uniQure (QURE)
(Real Time Quote from BATS)
$9.22 USD
+0.50 (5.73%)
Updated Jul 15, 2024 10:40 AM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
uniQure (QURE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.36 | $32.00 | $6.00 | 133.49% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for uniQure comes to $20.36. The forecasts range from a low of $6.00 to a high of $32.00. The average price target represents an increase of 133.49% from the last closing price of $8.72.
Analyst Price Targets (11)
Broker Rating
uniQure currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 69.23% and 7.69% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.54 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
5/8/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
5/8/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/7/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/2/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
4/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
3/4/2024 | Mizuho SecuritiesUSA | Uy D Ear | Hold | Hold |
2/29/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Hold |
2/28/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
12/21/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 13 |
Average Target Price | $20.36 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -1.24 |